Research & Development

The pharmaceutical landscape is rapidly evolving, and at the forefront of these advancements is Merck & Co.'s groundbreaking licensing agreement with Jiangsu Hengrui Pharmaceuticals, focusing on the innovative Lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. This monumental $2 billion deal puts

Retinitis pigmentosa, an inherited retinal disease, is characterized by progressive vision loss over time, ultimately leading to severe visual impairment. The disease affects the retinal photoreceptor cells, where the degeneration results in the gradual loss of night vision, peripheral vision, and

Breast cancer survivors are growing in number, thanks to early detection and effective treatments. However, alongside their survival, an undercurrent of accelerated aging has been observed, raising questions about the long-term impacts of the disease and its treatments on biological aging. This

Human evolution has always captured our imagination, leading to discoveries that continuously reshape our understanding of our origins. Researchers at the University of Cambridge have made a significant breakthrough, revealing that all modern humans share DNA from two ancient populations. These

Immunovant, a biotechnology company known for its innovative treatments for autoimmune diseases, has recently announced a significant shift in its development strategy. Despite late-stage successes with its experimental drug batoclimab, the company has decided to momentarily hold back on seeking

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that significantly impacts both liver and lung function, resulting in a rare but severe health burden. In an ambitious and promising development, Prime Medicine is leveraging its innovative gene editing technology to address this